Healthcare provider profile · identity verified

Reed A Mathias, MD

Allopathic & Osteopathic Physicians|Internal Medicine · GREENVILLE, SC · NPI 1174563704

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Reed A Mathias, MD received $19.61 in general payments during 2025 across 1 reported records.

PFIZER INC. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Eliquis by this doctor in 2024.

PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$19.61

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
PFIZER INC.	Unresolved — no canonical attribution shown	$19.61	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$19.61	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
ELIQUIS Normalized: eliquis	Drug	PFIZER INC.	$19.61	1	2025
Source payment records 2025-09-23 · PFIZER INC. · $19.61 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ELIQUIS eliquis	2025	Eliquis	2024	227	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
PFIZER INC. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063	Eliquis · 2024 Exact normalized brand match · 1 Part D row	227	53
PFIZER INC. Exact reporting entity; no affiliate inference	2025	PAXLOVID open payments reported associated product	CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432	Paxlovid · 2024 Exact normalized brand match · 1 Part D row	18	17

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	850	255
Levothyroxine Sodium	Levothyroxine Sodium	689	182
Rosuvastatin Calcium	Rosuvastatin Calcium	471	135
Omeprazole	Omeprazole	451	148
Amlodipine Besylate	Amlodipine Besylate	408	120
Losartan Potassium	Losartan Potassium	340	101
Lisinopril	Lisinopril	323	92
Gabapentin	Gabapentin	311	77
Metoprolol Succinate	Metoprolol Succinate	294	85
Simvastatin	Simvastatin	257	70
Eliquis	Apixaban	227	53
Hydrochlorothiazide	Hydrochlorothiazide	222	60
Tamsulosin Hcl	Tamsulosin Hcl	210	65
Metformin Hcl	Metformin Hcl	196	54
Pantoprazole Sodium	Pantoprazole Sodium	196	58
Furosemide	Furosemide	182	61
Lorazepam	Lorazepam	181	42
Escitalopram Oxalate	Escitalopram Oxalate	174	54
Pravastatin Sodium	Pravastatin Sodium	161	52
Zolpidem Tartrate	Zolpidem Tartrate	160	52
Meloxicam	Meloxicam	157	46
Montelukast Sodium	Montelukast Sodium	150	42
Alprazolam	Alprazolam	139	30
Potassium Chloride	Potassium Chloride	134	36
Carvedilol	Carvedilol	131	38
Metoprolol Tartrate	Metoprolol Tartrate	131	38
Duloxetine Hcl	Duloxetine Hcl	129	30
Fluticasone Propionate	Fluticasone Propionate	128	48
Clopidogrel	Clopidogrel Bisulfate	116	37
Famotidine	Famotidine	112	38
Metformin Hcl Er	Metformin Hcl	107	31
Ozempic	Semaglutide	105	23
Finasteride	Finasteride	104	33
Allopurinol	Allopurinol	103	34
Irbesartan	Irbesartan	102	31
Sertraline Hcl	Sertraline Hcl	98	27
Ezetimibe	Ezetimibe	97	30
Prednisone	Prednisone	88	64
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	86	26
Trazodone Hcl	Trazodone Hcl	86	27
Azithromycin	Azithromycin	80	65
Donepezil Hcl	Donepezil Hcl	76	26
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	73	21
Albuterol Sulfate Hfa	Albuterol Sulfate	72	38
Ramipril	Ramipril	71	18
Tramadol Hcl	Tramadol Hcl	70	24
Celecoxib	Celecoxib	68	24
Clonazepam	Clonazepam	68	18
Synthroid	Levothyroxine Sodium	65	22
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	64	19
Diclofenac Sodium	Diclofenac Sodium	61	26
Venlafaxine Hcl Er	Venlafaxine Hcl	57	17
Atenolol	Atenolol	56	15
Esomeprazole Magnesium	Esomeprazole Magnesium	56	18
Jardiance	Empagliflozin	55	16
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	54	17
Glipizide Er	Glipizide	53	17
Fluoxetine Hcl	Fluoxetine Hcl	52	16
Glipizide	Glipizide	51	14
Valsartan	Valsartan	50	16
Memantine Hcl	Memantine Hcl	49	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	48	12
Citalopram Hbr	Citalopram Hydrobromide	47	suppressed
Hydralazine Hcl	Hydralazine Hcl	44	13
Lansoprazole	Lansoprazole	44	14
Ondansetron Odt	Ondansetron	44	32
Tresiba Flextouch U-100	Insulin Degludec	44	suppressed
Xarelto	Rivaroxaban	43	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	42	15
Valacyclovir	Valacyclovir Hcl	42	20
Fenofibrate	Fenofibrate Nanocrystallized	41	11
Estradiol	Estradiol	40	12
Bupropion Xl	Bupropion Hcl	39	suppressed
Glimepiride	Glimepiride	39	12
Myrbetriq	Mirabegron	39	suppressed
Spironolactone	Spironolactone	38	14
Amitriptyline Hcl	Amitriptyline Hcl	36	suppressed
Chlorthalidone	Chlorthalidone	36	11
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	36	suppressed
Nitroglycerin	Nitroglycerin	36	20
Mirtazapine	Mirtazapine	35	suppressed
Mounjaro	Tirzepatide	35	suppressed
Azelastine Hcl	Azelastine Hcl	34	17
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	34	suppressed
Diazepam	Diazepam	34	suppressed
Ropinirole Hcl	Ropinirole Hcl	34	suppressed
Levetiracetam	Levetiracetam	32	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	32	30
Paroxetine Hcl	Paroxetine Hcl	32	suppressed
Linzess	Linaclotide	31	suppressed
Temazepam	Temazepam	31	suppressed
Pregabalin	Pregabalin	30	suppressed
Entresto	Sacubitril/Valsartan	29	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	29	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	29	18
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	28	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	28	suppressed
Buspirone Hcl	Buspirone Hcl	27	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	27	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	27	suppressed
Telmisartan	Telmisartan	27	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	17
Amoxicillin	Amoxicillin	26	21
Fenofibrate	Fenofibrate	26	suppressed
Cephalexin	Cephalexin	25	21
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	suppressed
Enalapril Maleate	Enalapril Maleate	24	suppressed
Fenofibrate	Fenofibrate,micronized	24	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	24	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	24	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	24	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Midodrine Hcl	Midodrine Hcl	23	suppressed
Nebivolol Hcl	Nebivolol Hcl	23	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	22	suppressed
Klor-Con M10	Potassium Chloride	22	suppressed
Klor-Con M20	Potassium Chloride	22	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	22	suppressed
Synjardy Xr	Empagliflozin/Metformin Hcl	22	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	21	17
Fluconazole	Fluconazole	21	19
Pioglitazone Hcl	Pioglitazone Hcl	21	suppressed
Sildenafil Citrate	Sildenafil Citrate	21	suppressed
Silodosin	Silodosin	21	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	21	suppressed
Testosterone Cypionate	Testosterone Cypionate	21	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	20	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	20	18
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	20	suppressed
Methylprednisolone	Methylprednisolone	20	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	14
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Xigduo Xr	Dapaglifloz Propaned/Metformin	19	suppressed
Bupropion Hcl Sr	Bupropion Hcl	18	suppressed
Colestipol Hcl	Colestipol Hcl	18	suppressed
Flecainide Acetate	Flecainide Acetate	18	suppressed
Humalog Kwikpen U-100	Insulin Lispro	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	18	suppressed
Levofloxacin	Levofloxacin	18	11
Paxlovid	Nirmatrelvir/Ritonavir	18	17
Tresiba Flextouch U-200	Insulin Degludec	18	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Baclofen	Baclofen	16	suppressed
Colchicine	Colchicine	16	12
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Premarin	Estrogens, Conjugated	16	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	15	suppressed
Meclizine Hcl	Meclizine Hcl	15	suppressed
Testosterone	Testosterone	15	suppressed
Verapamil Er	Verapamil Hcl	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	14	suppressed
Methotrexate	Methotrexate Sodium	14	suppressed
Modafinil	Modafinil	14	suppressed
Nystatin	Nystatin	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	suppressed
Dutasteride	Dutasteride	13	suppressed
Fluocinolone Acetonide Oil	Fluocinolone Acetonide Oil	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	13	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	13	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Synjardy	Empagliflozin/Metformin Hcl	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Anastrozole	Anastrozole	11	suppressed
Edarbi	Azilsartan Medoxomil	11	suppressed
Epinephrine	Epinephrine	11	suppressed
Glyburide	Glyburide	11	suppressed
Livalo	Pitavastatin Calcium	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Minocycline Hcl	Minocycline Hcl	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$19.61 · 1 records	PFIZER INC.	ELIQUIS	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Eliquis play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error